Successful, we will reply to you quickly.OK
Please select the quantity.OK
Your message is being sent, please wait.Close
Send mail failed, please send again!Close
Products are for research use only. Not for human use. We do not sell to patients.
(PF 04620110; PF04620110)
PF-04620110 Chemical Structure
|Product name: PF-04620110|
|Cat. No.: HY-13009|
PF-04620110 is an orally active, selective and potent diglyceride acyltransferase-1 (DGAT1) inhibitor with IC50 of 19 nM.
IC50 value: 19 nM 
PF-04620110 and imipramine (internal standard) were separated using a Hypersil Gold C18 column, with a mixture of acetonitrile and 10 mm ammonium formate (90:10, v/v) as the mobile phase. The ion transitions monitored in positive-ion mode [M + H](+) of multiple-reaction monitoring were m/z 397.0 → 260.2 for PF-04620110 and m/z 280.8 → 86.0 for imipramine. The detector response was specific and linear for PF-04620110 at concentrations within the range 0.05-50 μg/mL and the signal-to-noise ratios for the samples were ≥10 .
|M.Wt||396.44||Storage||Please store the product under the recommended conditions in the Certificate of Analysis.|
|Solvent & Solubility||
10 mM in DMSO
|1 mg||5 mg||10 mg|
|1 mM||2.5224 mL||12.6122 mL||25.2245 mL|
|5 mM||0.5045 mL||2.5224 mL||5.0449 mL|
|10 mM||0.2522 mL||1.2612 mL||2.5224 mL|
|Product Name||Sponsor Only||Condition||Start Date||End Date||Phase||Last Change Date|
|PF-04620110||Pfizer Inc||Non-insulin dependent diabetes||31-JUL-10||31-AUG-10||Phase 1||13-SEP-13|
|Pfizer Inc||Obesity||31-JUL-10||31-AUG-10||Phase 1||13-SEP-13|
|Pfizer Inc||Obesity||30-JUN-10||01-JAN-11||Phase 1||14-SEP-13|
|Pfizer Inc||Non-insulin dependent diabetes||30-JUN-10||01-JAN-11||Phase 1||14-SEP-13|
|Pfizer Inc||Obesity||30-JUN-11||31-AUG-11||Phase 1||14-SEP-13|
|Pfizer Inc||Non-insulin dependent diabetes||28-FEB-11||01-MAY-11||Phase 1||14-SEP-13|
. Lee KR, et al. Determination of PF-04620110, a novel inhibitor of diacylglycerol acyltransferase-1, in rat plasma using liquid chromatography-tandem mass spectrometry and its application in pharmacokinetic studies. Biomed Chromatogr. 2013 Jul;27(7):846-52.
A 922500 is a potent, selective, and orally bioavailable DGAT-1 inhibitor with IC50 values of 7 nM and 24 nM for human and mouse DGAT-1 respectively.
ABT-046 is a potent, selective, and orally bioavailable Diacylglycerol acyltransferase 1 (DGAT-1 ) inhibitor (IC50= 8 nM).
AZD7687 is a potent and selective DGAT1 inhibitor with an IC50 value of 80 nM (hDGAT1).
DGAT1-IN-1 is a potent DGAT1 inhibitor with IC50 of < 10 nM(cell lysate from Hep3B cells overexpressing human DGAT1).
LCQ-908 is a new generation of diacylglycerol acyltransferase 1 (DGAT1) inhibitor as anti-obesity and anti-diabetic agents.
T-863(DGAT-1 inhibitor) is an orally active, selective and potent DGAT1 (Acyl-CoA:diacylglycerol acyltransferase 1) inhibitor that interacts with the acyl-CoA binding site of DGAT1, and inhibits triacylglycerol synthesis in cells.
Xanthohumol is one of the principal flavonoids isolated from hops, the inhibitor of diacylglycerol acetyltransferase (DGAT), COX-1 and COX-2, and shows anti-cancer and anti-angiogenic activities.